Paritaprevir

CAT:
804-HY-12594-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Paritaprevir - image 1

Paritaprevir

  • Description :

    Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [1][2][3][4].
  • Product Name Alternative :

    ABT-450; Veruprevir
  • UNSPSC :

    12352005
  • Hazard Statement :

    H302, H315, H319, H335
  • Target :

    HCV; HCV Protease; SARS-CoV
  • Type :

    Reference compound
  • Related Pathways :

    Anti-infection; Metabolic Enzyme/Protease
  • Applications :

    COVID-19-anti-virus
  • Field of Research :

    Infection
  • Assay Protocol :

    https://www.medchemexpress.com/Paritaprevir.html
  • Purity :

    99.87
  • Solubility :

    DMSO : ≥ 125 mg/mL|H2O : < 0.1 mg/mL
  • Smiles :

    O=C([C@]1(NC([C@@]2([H])N3C[C@H](OC4=C(C=CC=C5)C5=C6C(C=CC=C6)=N4)C2)=O)[C@H](/C=C\CCCCC[C@H](NC(C7=NC=C(C)N=C7)=O)C3=O)C1)NS(=O)(C8CC8)=O
  • Molecular Formula :

    C40H43N7O7S
  • Molecular Weight :

    765.88
  • Precautions :

    H302, H315, H319, H335
  • References & Citations :

    [1]Smith MA, et al. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083-94.|[2]Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[4]Menon RM, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015 Jul;63 (1) :20-9.
  • Shipping Conditions :

    Room Temperature
  • Storage Conditions :

    4°C (Powder, sealed storage, away from moisture and light)
  • Scientific Category :

    Reference compound1
  • Clinical Information :

    Launched
  • CAS Number :

    [1216941-48-8]